Analytical Method Development and Validation of Remdesivir and Griseofulvin in API and its Dosage Form by RP-HPLC

Background: The suggested approach is appropriate for the quantitative measurement of Remdesivir and Griseofulvin in a variety of pharmaceutical dosage forms, according to experimental findings. The technique offers excellent repeatability, linearity, and sensitivity. Remdesivir and Griseofulvin were estimated using RP-HPLC. Objective: The objective was to accomplish method development and validation of Remdesivir and Griseofulvin. Materials and Methods: The mobile phase was adjusted and consisted of acetonitrile and phosphate buffer mixed in a 70:30% v/v ratio. 4.6 was the pH of the phosphate buffer. An X Terra Symmetry C18 (4.6 x 250mm, 5µm) column is used as the stationary phase. For the detection, a UV detector tuned to 221 nm was employed. Chromatography of the solutions was performed at a constant flow rate of 1.0 ml/min. Many trials have been carried out to obtain an optimized chromatogram. Results: Remdesivir and Griseofulvin were reported to have linearity ranges of 25-125 µg/ml. There was no increase in the linear regression coefficient above 0.999. The accuracy and precision of the procedure are indicated by the percentage RSD readings being less than 2%. The percentage recovery for Griseofulvin and Remdesivir ranges from 97 to 100%. It was discovered that LOD and LOQ were inside the range. Conclusion: The suggested technique for figuring out how much Remdesivir and Griseofulvin are in a formulation is exact, easy to use, and accurate. A high recovery rate indicates that the formulation's excipients are not interfering with the process. Therefore, the technique may be helpful for routinely checking the quality of these medications.